Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Sarcoma 1Retinoblastoma 1Optic Nerve Glioma 1Oligodendroglioma 1Neuroblastoma 1Medulloblastoma 1Lymphoma 1Familial ependymoma 1Dendritic Cell Sarcoma, Interdigitating 1Choroid Plexus Neoplasms 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1Astrocytoma 1

Interventions

Irinotecan 31Paclitaxel 27Gemcitabine 27Cisplatin 25Docetaxel 20Oxaliplatin 16Fluorouracil 15alvocidib 13Leucovorin 13Carboplatin 13Capecitabine 12Bortezomib 10Early Intervention, Educational 9Topotecan 8Taxes 8Bevacizumab 73-aminopyridine-2-carboxaldehyde thiosemicarbazone 7ixabepilone 6Vorinostat 6Temozolomide 6Sorafenib 6Immunohistochemistry 6Immunoenzyme Techniques 67-hydroxystaurosporine 6tanespimycin 5Pharmacogenomic Testing 5Pemetrexed 5Magnetic Resonance Spectroscopy 5Filgrastim 5Etoposide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unspecified Adult Solid Tumor, Protocol Specific × becatecarin × Other solid neoplasm × Clear all
NCT00086983 2013-01-10

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

National Cancer Institute (NCI)

Phase 1 Terminated
15 enrolled
Other solid neoplasm

Unspecified Adult Solid Tumor, Protocol Specific

Data powered by HemOnc (CC BY 4.0) Colophon âš¡